EFung Capital

Summary

In 1996 was created EFung Capital, which is appeared as VC. The company was established in Asia in China. The main department of described VC is located in the Shenzhen.

Speaking about the real fund results, this VC is 12 percentage points less often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 investment rounds annually. This EFung Capital works on 14 percentage points less the average amount of lead investments comparing to the other organizations. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The higher amount of exits for fund were in 2001.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the EFung Capital, startups are often financed by InterWest Partners, Shenzhen Capital Group, Quan Capital. The meaningful sponsors for the fund in investment in the same round are Panacea Venture, YuanMing Capital, Viventures. In the next rounds fund is usually obtained by YuanMing Capital, State Development & Investment Corporation (SDIC), RMB Funds.

We also calculated 4 valuable employees in our database.

The fund has no exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Biopharma, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Centrexion, Elicio Therapeutics, Resverlogix.